►Trethera is a clinical-stage biopharmaceutical company led by an experienced drug development team and founded by recognized UCLA faculty successful in bringing medical products to market. Focusing on the pathways controlling nucleotide metabolism led to the development of TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK) as a multidimensional drug which potentially treats autoimmune diseases and cancers.
►By targeting multiple pathways using rationally-designed combinations of drugs, Trethera’s therapeutic approaches are designed to improve efficacy and overcome the limitations of previous single agent therapies.